Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPO | P22079 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 2/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | C1S | P09871 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL569909 | 0.77 | LPO (0.43) | LPOFDPSMCL1C1SKMT2A | |
| SCHEMBL5610390 | 0.71 | LPO (0.41) | LPOFDPSMCL1C1SKMT2A | |
| SCHEMBL604082 | 0.71 | LPO (0.41) | LPOFDPSMCL1C1SKMT2A | |
| SCHEMBL9033147 | 0.71 | LPO (0.41) | LPOFDPSMCL1C1SKMT2A | |
| SCHEMBL5610393 | 0.71 | LPO (0.41) | LPOFDPSMCL1C1SHTT | |
| SCHEMBL20368151 | 0.70 | HTT (0.41) | LPOFDPSMCL1C1SKMT2A | |
| Hydrochloric Acid SCHEMBL28316626 | 0.70 | LPO (0.40) | LPOFDPSMCL1C1SKMT2A | |
| Hydrochloric Acid SCHEMBL4002547 | 0.69 | TSHR (0.37) | LPOFDPSMCL1C1SHTT | |
| SCHEMBL24051973 | 0.68 | MCL1 (0.46) | LPOFDPSMCL1C1SKMT2A | |
| SCHEMBL22951445 | 0.68 | MCL1 (0.40) | LPOFDPSMCL1C1SKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | LPO 4870/4885FDPS 2675/4885MCL1 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.